Can You Take HRT After Melanoma? Recurrence, Risk and What to Ask

Can you take HRT after melanoma? For many women treated for early-stage melanoma, it can be considered. Melanoma isn't a listed contraindication on the US estrogen labels we read. A 2026 review in Menopause lists melanoma among cancers where systemic hormone therapy can be offered, though the evidence is thin. Decide together with your oncologist or dermatologist.

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

What we actually verified · Last verified October 2026

• What we read: the full text of a 2004 Scottish study of HRT in 206 women treated for stage 1 or 2 melanoma; a 2026 Menopause review of hormone therapy in cancer survivors; a 2023 Spanish Menopause Society review of HRT after colorectal, lung and melanoma cancers; the published abstracts of the Women's Health Initiative skin cancer analysis, nationwide studies from Norway (2017) and Finland (2019), a 2020 meta-analysis and a 2016 Mayo Clinic review; the 2024 British Gynaecological Cancer Society and British Menopause Society guideline on HRT after gynecological cancer; American Cancer Society, National Cancer Institute and SEER pages on melanoma; The Menopause Society's 2022 hormone therapy and 2023 nonhormone therapy position statements; and the FDA labels for Premarin, Prempro, Prometrium, Climara, Vivelle-Dot and Estrace cream. Every source is listed at the bottom with the date we read it.
• What we did not do: we did not examine anyone, look at anyone's skin, pathology reports, scans or records, or speak with a clinician for this page. This is editorial research, not medical review, and not advice for your situation.
• Commercial interest: The HRT Index may earn a commission from some providers featured through The HRT Index's Find My HRT Path tool. No provider paid for this page, and no provider reviewed it. See our affiliate disclosure.
• Verification Standard: we judge online menopause care on five pillars, in this order: clinical legitimacy, care quality, medication fit, price transparency and access. Our methodology explains how.

Jump to: Quick answer by situation · Melanoma basics · Why hormones come up · HRT and new melanoma risk · HRT after melanoma · Estrogen-only vs combined · Patch, pill or gel · Vaginal estrogen · Nonhormonal options · Skin checks and red flags · Who shouldn't take HRT · Questions to ask · Online care · FAQ · Sources

Can you take HRT after melanoma? A quick answer for your situation

The answer depends mostly on the stage of your melanoma, where it was, and whether you're still in treatment. This table sums up what the sources below say. It's a starting point for a conversation with your treating team, not a decision.

Bottom line for most women: early-stage melanoma that's been treated doesn't automatically rule out HRT, but the decision belongs with your melanoma team as well as your menopause prescriber.

The right online menopause care isn't the same for every woman — it depends on your symptoms, what you've already tried, your age, your state and your health history. Some situations belong with an in-person clinician first. Use The HRT Index's Find My HRT Path tool to explore a featured care option for your situation — and to flag when online care isn't the right starting point — before your first consult.

Find My HRT Path is free, takes about 60 seconds and doesn't ask for your email. It asks about your symptoms, what you've already tried, your age, your state and your health history, and you can choose "I'd rather discuss my health history with a clinician." It isn't an eligibility test or a diagnosis.

Melanoma basics: what your stage means for HRT

Melanoma is a cancer that starts in melanocytes, the cells that make skin pigment. Most melanomas start in the skin, which is the kind nearly all the HRT research covers.

It's common in women before and around menopause

The American Cancer Society (ACS) estimates about 112,000 new melanomas will be diagnosed in the US in 2026, about 46,600 of them in women. The ACS says melanoma "is one of the most common cancers in young adults, especially young women," and that it's more common in women than in men before age 50. The average age at diagnosis is 67.

That means many women face menopause after a melanoma diagnosis, or get a melanoma diagnosis while already on HRT.

Most melanomas are found early

According to the National Cancer Institute's SEER program, 77% of skin melanomas are found while still confined to the primary site (localized), 10% after spreading to nearby lymph nodes, and 5% after spreading to distant parts of the body. The rest are unstaged. The overall five-year relative survival is 94.7%.

Stages in plain language

The National Cancer Institute's patient guide describes these stages:

• Stage 0 (melanoma in situ): abnormal melanocytes are found only in the outer layer of the skin.
• Stages 1 and 2: the cancer is in the skin. The stage depends on how thick the tumor is and whether its surface is broken down (ulcerated).
• Stage 3: the cancer has spread to nearby lymph nodes or nearby skin.
• Stage 4: the cancer has spread to other parts of the body, such as the lungs, liver, brain or bone.

Treatment can include surgery, immunotherapy, targeted therapy, radiation therapy and chemotherapy. Most of the HRT research, including the only study of HRT after melanoma, involved women with stage 1 or 2 disease treated with surgery. That's why the stage on your pathology report matters so much for this decision.

Why hormones come up with melanoma

For decades, many clinicians were cautious about HRT after melanoma. A 2004 Scottish study noted that HRT package inserts in the UK at the time warned of caution in women with a history of melanoma, while the British National Formulary admitted that "evidence for caution in melanoma is unsatisfactory and many women may stand to benefit from HRT."

The worry came from a few observations. Melanoma is more common in women than in men at younger ages, and some studies have linked estrogen use to a higher chance of being diagnosed with melanoma.

But the biology isn't simple. A 2023 review by the Spanish Menopause Society notes that skin contains more estrogen receptor beta (ERβ) than estrogen receptor alpha. Unlike breast tissue, where alpha receptors predominate, the beta receptors in skin may reduce tumor growth, according to that review. A 2016 Mayo Clinic review makes the broader point that estrogen receptors in a cancer type "does not always result in estrogen-mediated tumor proliferation and adverse cancer-related outcomes."

In short, the guidance we read doesn't treat melanoma the way it treats estrogen receptor positive breast cancer, where systemic HRT generally isn't prescribed. But no large trial in melanoma survivors has settled the question either.

What studies show about HRT and the risk of a new melanoma

These studies looked at women who had never had melanoma, asking whether HRT users were more likely to be diagnosed with one. They don't directly answer what happens after melanoma, but they're the background your clinicians will have in mind.

How to read those numbers

These are relative numbers. A 14% to 45% increase in a risk sounds large, but it's applied to a person's baseline chance of melanoma, which depends heavily on sun exposure, skin type, moles and family history. None of these studies reported an absolute increase that we could translate into "extra cases per 1,000 women" for this page, so we haven't invented one.

Why the studies disagree

• Randomized vs observational: the Women's Health Initiative was the only randomized trial, and it found no effect. Its authors concluded that their findings "do not support a role of menopausal estrogen, with or without progestin, in the development of skin cancer." But melanoma wasn't its main outcome, there were only 95 melanomas, and the analysis was done after the fact.
• Who uses HRT: the observational studies can't fully rule out that women on HRT see doctors more, get more skin checks, or differ in sun exposure. More checks can mean more melanomas found.
• Estrogen-only vs combined: both Nordic studies found the signal mainly with estrogen-only therapy. The Norwegian authors concluded that "estrogens and progestins might affect the risk of SMM [skin melanoma] in opposite ways."

What's known about HRT after melanoma

This is the question you're actually asking: if you've already had melanoma, does HRT make it more likely to come back or shorten survival? The honest answer is that the direct evidence comes from one small study, plus expert reviews built on it.

The one study of women who'd had melanoma

In 2004, MacKie and Bray published a study in the British Journal of Cancer of women in the west of Scotland treated for stage 1 or 2 skin melanoma between 1990 and 1995. They followed 206 women, born between 1935 and 1950, for a median of 10.6 years.

• 83 women used HRT at some point after their melanoma (62 combined HRT, 21 estrogen-only after hysterectomy), mostly for less than 3 years.
• 123 women did not use HRT.
• One woman in the HRT group died of melanoma, compared with 22 in the no-HRT group.
• After adjusting for tumor thickness, ulceration and age, the HRT group still had better survival (hazard ratio 0.173, 95% CI 0.048–0.621).

The authors concluded that "HRT after melanoma does not adversely affect prognosis," and that women "who have had stage 1 or 2 melanoma successfully treated should be considered for HRT in the same way as those who have never had melanoma."

Keep the limits in mind. This wasn't a randomized trial. Doctors chose who got HRT, and the HRT group was younger and had fewer ulcerated tumors. So the survival advantage shouldn't be read as HRT protecting against melanoma. The reassuring part is that there was no sign of harm.

What expert reviews conclude

The 2026 Menopause review also advises: "Involve the oncology team in the decision regarding symptom relief, especially if therapy is ongoing."

Putting it together

• Treated stage 0, 1 or 2 skin melanoma: HRT can generally be considered, with your dermatologist or oncologist involved.
• Stage 3 or 4, or still in treatment: the evidence above mostly doesn't cover you. Your oncologist should lead the decision.
• Vulvar, mucosal or eye melanoma: the evidence is thinnest here. Ask your specialist.

The Spanish review also cites the higher risk of a new melanoma linked to HRT in some studies, and still concluded that women with a history of melanoma are eligible. That's the trade-off your clinicians will weigh: a possible small increase in the chance of a new melanoma against real relief from symptoms, with regular skin checks either way.

Estrogen-only vs combined HRT

The studies above raise one practical question: does it matter which kind of HRT you take?

• If you have a uterus, you need a progestogen with systemic estrogen to protect the uterine lining. The 2026 Menopause review says that in women with a uterus, "systemic estrogen requires endometrial protection with a progestogen or bazedoxifene." In the Nordic studies, combined estrogen-plus-progestin therapy wasn't linked to higher melanoma risk in the first few years.
• If you've had a hysterectomy, you'd usually take estrogen alone. That's the type linked to higher risk of a new melanoma in the Norwegian and Finnish studies. It was also not linked to any increase in the Women's Health Initiative estrogen-alone trial.

No study we found tested whether adding a progestogen helps women who've already had melanoma, and adding one when you don't have a uterus brings its own side effects and risks. Don't change your HRT type on your own. If you've had a hysterectomy and melanoma, ask your clinicians how they read the estrogen-only data for you.

See estrogen-only vs estrogen plus progesterone, do you need progesterone if you have a uterus? and progestin vs progesterone.

Patch, pill or gel: does the route matter?

For melanoma specifically, the route doesn't seem to change the picture. The Finnish study "did not find significant differences between oral and transdermal administrations, nor between doses of estrogens." In a dose analysis of women using tablets, the Norwegian study found a higher risk with higher estrogen doses (RR 1.24 per 1 mg a day).

For other reasons, the 2026 Menopause review says "transdermal ET is preferred over oral options because of lower venous thromboembolic (VTE) and metabolic risk" in cancer survivors. The review notes that surgery, targeted therapy and hospital stays are among the things that can raise clot risk in people with cancer, so that's worth raising with your team.

The Menopause Society's 2022 position statement says that for women younger than 60, or within 10 years of menopause onset, without contraindications, "the benefit-risk ratio is favorable for treatment of bothersome VMS and prevention of bone loss." The lowest dose that controls your symptoms is a reasonable thing to ask about.

Vaginal estrogen after melanoma

If your main symptoms are vaginal dryness, irritation, urinary symptoms or painful sex, low-dose vaginal estrogen is a separate question from systemic HRT.

• The Menopause Society's 2022 statement says low-dose vaginal estrogen is "effective and generally safe" for these symptoms, "with minimal systemic absorption."
• The 2026 Menopause review says low-dose vaginal estrogen "can be used in most survivors of cancer," with exceptions that don't include melanoma.
• The UK guideline says vaginal estrogens are safe for most women after gynecological cancer treatment, including many for whom systemic HRT isn't advised.

One caveat: the 2017 Norwegian study found a higher rate of new melanoma among women using vaginal estrogen products (RR 1.44). That was an observational study of women who hadn't had melanoma, and it can't separate the product from other differences between users. Ask your clinicians how they weigh it. Progestogen isn't needed with low-dose vaginal estrogen under The Menopause Society's guidance.

See vaginal estrogen vs systemic estrogen and do you need progesterone with vaginal estrogen?.

If you'd rather avoid hormones

Some women who've had melanoma, or their doctors, would rather not use hormones. The Menopause Society's 2023 nonhormone therapy position statement recommends these options for hot flashes and night sweats:

The statement doesn't recommend supplements or herbal remedies, soy foods, cooling techniques or paced breathing for hot flashes. If you're on melanoma treatment, ask your oncologist how any new medicine fits with it. See nonhormonal options and fezolinetant for hot flashes.

Skin checks and signs that need prompt care

Whatever you decide about HRT, follow-up after melanoma matters. The ACS says people who've had melanoma are at higher risk of a new melanoma or another skin cancer.

• Self-exams: the ACS says it's important to do regular self-exams of your skin and lymph nodes, and "most doctors recommend this at least monthly."
• Clinic visits: after early-stage melanoma that was removed completely, a typical schedule "might call for physical exams every 6 to 12 months for several years." Thicker or spread melanomas might need exams every 3 to 6 months, sometimes with imaging.
• Sun protection: the ACS advises limiting UV exposure from the sun and tanning beds.

See your doctor promptly if you notice:

• A new mole, or a mole or spot that changes
• A new lump, including in the neck, armpit or groin
• Symptoms the ACS lists as possible signs that melanoma has come back elsewhere: pain, cough, shortness of breath, fatigue, loss of appetite, headaches or swelling in the abdomen

Several of these overlap with menopause or other common problems, such as fatigue or headaches. But if you've had melanoma, they're worth reporting rather than putting down to menopause or HRT. If you start HRT, keep your skin checks on schedule.

Who shouldn't take HRT, whatever their melanoma history

Melanoma isn't named on the US estrogen and progesterone labels we read, but the usual reasons not to take estrogen still apply. The Climara label lists these contraindications:

• Undiagnosed abnormal genital bleeding
• Breast cancer or a history of breast cancer
• Estrogen-dependent cancer
• An active DVT or PE, or a history of one
• Active arterial clotting disease, such as a stroke or heart attack, or a history of one
• A known severe allergic reaction to the product
• Liver problems or liver disease
• Protein C, protein S or antithrombin deficiency, or another known clotting disorder

The Prometrium label also says its capsules contain peanut oil, so they shouldn't be used by people allergic to peanuts.

Online services may set their own stricter rules. For example, one service's estradiol patch guides, as captured by The HRT Index in August 2026, listed metastatic melanoma among conditions that should stop treatment and prompt contact. If your melanoma has spread, expect an online prescriber to want your oncologist involved, or to send you to in-person care.

See who should not take HRT and HRT contraindications for more.

Questions to ask your dermatologist, oncologist and menopause clinician

Bring these to your appointments, and talk with your clinicians about how they apply to you:

1. What stage was my melanoma, how thick was it, and was it ulcerated?
2. Am I still in treatment, or in follow-up only? How long until you'd consider my risk of recurrence low?
3. Is there any reason, given my melanoma, that I shouldn't use systemic estrogen?
4. If I've had a hysterectomy, how do you read the estrogen-only data for me?
5. Would a patch or gel be better for me than a pill, given my clot risk?
6. Would low-dose vaginal estrogen cover my symptoms instead?
7. If I start HRT, how often should my skin and lymph nodes be checked?
8. If I'd rather not take hormones, which nonhormonal options fit with my melanoma care?

Can online menopause care help after melanoma?

Online care can help with the menopause part of the picture, but it doesn't replace your skin checks or your cancer follow-up. Here's how our five pillars apply:

• Clinical legitimacy: a licensed clinician should take a full health history, including your melanoma's stage, where it was, how it was treated and when, before prescribing anything.
• Care quality: look for a service that will coordinate with your dermatologist or oncologist and set a clear plan for what happens if a new skin change or recurrence turns up.
• Medication fit: the service should offer patches or gels as well as pills, progestogen choices if you have a uterus, and vaginal and nonhormonal options.
• Price transparency: you should know what visits, refills and lab work cost before you start.
• Access: you'll still need in-person skin exams and any imaging your melanoma team recommends. Online menopause care should fit alongside that, not replace it.

See is online HRT safe? for more on how to judge a service, and HRT side effects for what to watch for after starting.

Frequently asked questions

Can you take HRT after melanoma?

Often it can be considered, especially after early-stage skin melanoma that's been treated. Melanoma isn't a listed contraindication on the US estrogen labels we read, and the only study of HRT after melanoma found no worse survival. The evidence is limited, so decide with your dermatologist or oncologist and a menopause clinician.

Does HRT cause melanoma?

It hasn't been shown to. The Women's Health Initiative randomized trials found no effect on melanoma. Some large observational studies found a small relative increase in new melanomas among HRT users, mainly with estrogen-only therapy, but they can't prove cause.

Does HRT make melanoma come back?

There's no good evidence that it does. The one study of women treated for stage 1 or 2 melanoma found one melanoma death among 83 HRT users and 22 among 123 non-users. It wasn't randomized and was small, so it can't prove safety, but it showed no sign of harm.

Is melanoma a hormone-sensitive cancer?

Guidance doesn't treat it like estrogen receptor positive breast cancer. A Spanish review notes that skin contains more estrogen receptor beta, which may restrain tumor growth rather than drive it. The 2026 Menopause review lists melanoma among cancers where systemic hormone therapy can be offered.

How long after melanoma can I start HRT?

No guideline we read sets a waiting period. Ask your oncologist or dermatologist when your recurrence risk is low enough for them to be comfortable.

Can I use vaginal estrogen after melanoma?

Probably, in most cases. The 2026 Menopause review says low-dose vaginal estrogen can be used in most cancer survivors, and melanoma isn't among its exceptions. One Norwegian study linked vaginal estrogen to more new melanomas in women without a history, so ask your clinicians how they weigh that.

What if my melanoma was stage 3 or 4?

The reviews we read mostly cover localized melanoma, so there's much less to go on. Your oncologist should lead this decision. Nonhormonal treatments may be a reasonable first step while you discuss it.

Can Find My HRT Path tell me if HRT is safe after my melanoma?

No. Find My HRT Path asks about menopause symptoms, what you've tried, your age, your state and your health history. It doesn't assess cancer risk or decide on a prescription. A clinician who knows your full history, working with your melanoma team, can do that.

The bottom line

Can you take HRT after melanoma? For many women, especially after early-stage skin melanoma that's been treated, it can be considered. Melanoma isn't a listed contraindication on the US estrogen labels we read, and recent expert reviews say systemic hormone therapy can be offered. But the evidence is thinner than those conclusions might suggest: one small, non-randomized study of women who'd had melanoma, plus large studies linking estrogen-only HRT to a small relative increase in new melanomas. The things that matter most are your stage, whether you're still in treatment, whether you need estrogen alone or combined HRT, whether a vaginal or nonhormonal option would do, and keeping up your skin checks. Talk about all of these with your dermatologist or oncologist and your menopause clinician.

If you're figuring out where menopause care fits alongside your melanoma follow-up, Find My HRT Path can help you see what fits and flag when in-person care should come first.

Related reading

• Who should not take HRT
• Estrogen-only vs estrogen plus progesterone
• Vaginal estrogen vs systemic estrogen
• HRT after hysterectomy
• HRT and colorectal cancer risk
• HRT after cervical cancer
• Menopause treatment for breast cancer survivors online
• Nonhormonal options

Sources

All sources were read on October 30, 2026.

1. MacKie RM, Bray CA. Hormone replacement therapy after surgery for stage 1 or 2 cutaneous melanoma. British Journal of Cancer, 2004;90(4):770–772. https://pmc.ncbi.nlm.nih.gov/articles/PMC2410176/
2. Christmas M. Hormone therapy use and cancer survivorship. Menopause, 2026;33(8):932–934. https://pmc.ncbi.nlm.nih.gov/articles/PMC13395264/
3. Fiol G, et al. Associations between menopausal hormone therapy and colorectal, lung, or melanoma cancer recurrence and mortality: a narrative review. Journal of Clinical Medicine, 2023;12(16):5263. https://pmc.ncbi.nlm.nih.gov/articles/PMC10455141/
4. Kuhle CL, Kapoor E, Sood R, Thielen JM, Jatoi A, Faubion SS. Menopausal hormone therapy in cancer survivors: a narrative review of the literature. Maturitas, 2016;92:86–96. https://pubmed.ncbi.nlm.nih.gov/27621244/
5. Tang JY, Spaunhurst KM, Chlebowski RT, et al. Menopausal hormone therapy and risks of melanoma and nonmelanoma skin cancers: Women's Health Initiative randomized trials. Journal of the National Cancer Institute, 2011;103(19):1469–1475. https://pmc.ncbi.nlm.nih.gov/articles/PMC3186783/
6. Botteri E, Støer NC, Sakshaug S, et al. Menopausal hormone therapy and risk of melanoma: do estrogens and progestins have a different role? International Journal of Cancer, 2017;141(9):1763–1770. https://pubmed.ncbi.nlm.nih.gov/28685818/
7. Botteri E, Støer NC, Weiderpass E, Pukkala E, Ylikorkala O, Lyytinen H. Menopausal hormone therapy and risk of melanoma: a nationwide register-based study in Finland. Cancer Epidemiology, Biomarkers & Prevention, 2019;28(11):1857–1860. https://pubmed.ncbi.nlm.nih.gov/31455672/
8. Tang X, Zhang H, Cui Y, et al. Postmenopausal exogenous hormone therapy and melanoma risk in women: a systematic review and time-response meta-analysis. Pharmacological Research, 2020;160:105182. https://pubmed.ncbi.nlm.nih.gov/32890740/
9. Taylor A, et al. British Gynaecological Cancer Society and British Menopause Society guidelines: management of menopausal symptoms following treatment of gynaecological cancer. Post Reproductive Health, 2024;30(4):256–279. https://pubmed.ncbi.nlm.nih.gov/39394654/
10. American Cancer Society. Key statistics for melanoma skin cancer. https://www.cancer.org/cancer/types/melanoma-skin-cancer/key-statistics.html
11. American Cancer Society. After treatment for melanoma. https://www.cancer.org/cancer/types/melanoma-skin-cancer/after-treatment.html
12. National Cancer Institute. Melanoma treatment (PDQ), patient version. https://www.cancer.gov/types/skin/patient/melanoma-treatment-pdq
13. National Cancer Institute, SEER Program. Cancer stat facts: melanoma of the skin. https://seer.cancer.gov/statfacts/html/melan.html
14. The 2022 hormone therapy position statement of The North American Menopause Society (The Menopause Society). Menopause, 2022;29(7):767–794. https://menopause.org/wp-content/uploads/professional/nams-2022-hormone-therapy-position-statement.pdf
15. The 2023 nonhormone therapy position statement of The North American Menopause Society (The Menopause Society). Menopause, 2023;30(6):573–590. https://menopause.org/wp-content/uploads/professional/2023-nonhormone-therapy-position-statement.pdf
16. Premarin (conjugated estrogens tablets) prescribing information. DailyMed, US National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=258e1602-a3cf-4ccc-ca80-73dbbfb812ff
17. Prempro and Premphase (conjugated estrogens/medroxyprogesterone acetate tablets) prescribing information. DailyMed, US National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd0c0836-5d23-2183-da81-9dc7f4287052
18. Prometrium (progesterone capsules) prescribing information. DailyMed, US National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1cf237ff-c4f8-4faa-a7aa-77599c856889
19. Climara (estradiol transdermal system) prescribing information. DailyMed, US National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e9702c4-f2d7-4ea8-b6e8-7dca31671864
20. Vivelle-Dot (estradiol transdermal system) prescribing information. DailyMed, US National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5ccb77f9-d47b-4381-ad5c-5b92524e1c4a
21. Estrace (estradiol vaginal cream) prescribing information. DailyMed, US National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dfc41fcd-c5ba-4b25-b647-cf04d3988b3e

This page is for education only and is not medical advice. It doesn't replace an examination, diagnosis or treatment plan from a clinician who knows your health history. If you notice a new or changing mole, a new lump, or new symptoms after melanoma treatment, contact your dermatologist or oncologist promptly.